MedStar Authors catalog › Details for: Second-Generation Drug-Eluting Resorbable Magnesium Scaffold: Review of the Clinical Evidence. [Review]
Normal view MARC view ISBD view

Second-Generation Drug-Eluting Resorbable Magnesium Scaffold: Review of the Clinical Evidence. [Review]

by Garcia-Garcia, Hector M; Hideo-Kajita, Alexandre; Ozaki, Yuichi; Shlofmitz, Evan; Waksman, Ron.
Citation: ; Cardiovascular Revascularization Medicine. 21(1):127-136, 2020 01..Journal: Cardiovascular revascularization medicine : including molecular interventions.Published: ; 2020; ; ISSN: 1878-0938.Full author list: Garcia-Garcia HM; Hideo-Kajita A; Ozaki Y; Shlofmitz E; Waksman R.UI/PMID: 31662277.Subject(s): *Absorbable Implants | Treatment Outcome | Risk Factors | Prosthesis Design | *Percutaneous Coronary Intervention/mo [Mortality] | Percutaneous Coronary Intervention/ae [Adverse Effects] | *Magnesium | Humans | *Coronary Artery Disease/th [Therapy] | Coronary Artery Disease/dg [Diagnostic Imaging] | *Coated Materials, Biocompatible | Cardiovascular Agents/ae [Adverse Effects] | *Cardiovascular Agents/ad [Administration & Dosage] | AnimalsInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal Article | ReviewDigital Object Identifier: (Click here) Abbreviated citation: ; Cardiovasc Revasc Med. 21(1):127-136, 2020 01.Local Holdings: Available in print through MWHC library: 2002 - present.Abstract: Since October 8, 2013, the second-generation drug-eluting resorbable magnesium scaffold (RMS) has been used to treat coronary lesions. At present, the second-generation drug-eluting RMS is clinically available in Europe, some South American countries, and some Asian and African countries. Furthermore, patients are currently being enrolled in ongoing post-marketing trials. This device has the potential to be an alternative to drug-eluting stents in the future, but there is not yet sufficient evidence. This review provides the latest available evidence, comparison with other bioresorbable scaffolds, future perspectives, and discussion of clinical case reports with second-generation drug-eluting RMS. SUMMARY: Favorable outcomes have been reported after second-generation drug-eluting RMS implantation. More long-term clinical outcomes for this novel device are still required in the future. Copyright (c) 2019 Elsevier Inc. All rights reserved.

Powered by Koha